https://doi.org/10.47552/ijam.v16iS2.6197 ISSN No: 0976-5921

Int J. of Ayurvedic Med, "Natural to Synthetic: The Convergence of Traditional Medicine to Modern Medicine" Supplement 2025

Psychedelic Herbal Medicines: Exploring the Renaissance of a Therapeutic Frontier

Review Article

Gaurav Mude[1]*, Shantilal Singune[1], Raghvendra Dubey[1]

1. Institute of Pharmaceutical Sciences, SAGE University, Indore (MP), India.

Abstract

A revolutionary change in contemporary therapeutic paradigms may be seen in the renewed interest in psychedelic plant remedies. Psychedelic plants like psilocybe mushrooms, ayahuasca, iboga, and salvia divinorum, which have long been valued for their spiritual and therapeutic qualities in a variety of cultures, are now the subject of intense scientific research. According to recent clinical research, they have great promise for treating a variety of illnesses, such as addiction, PTSD, anxiety, and depression. This resurgence is fuelled by mounting evidence that these drugs may support profound psychological healing, emotional resilience, and neuroplasticity when used under careful supervision. Technological developments in ethnobotany, neurology, and psychopharmacology are revealing the intricate processes by which these herbal psychedelics work, particularly via serotonergic pathway regulation and the amplification of introspective experiences. The regulatory environment is gradually changing, indicating a cautious sense of hope about the incorporation of these traditional medicines into contemporary medical treatment. But there are still issues to be resolved, such as standardising botanical formulations, guaranteeing patient safety, and tackling the social stigma attached to psychedelics. This study highlights the need for multidisciplinary cooperation in furthering this exciting field by examining the historical origins, molecular foundations, therapeutic uses, and potential future developments of psychedelic plant medicines. Psychedelic herbal treatments provide a rare chance to rethink mental health therapy by fusing ancient wisdom with modern research, paving the door for more individualised and holistic approaches to recovery.

Keywords: Psychedelic Herbal Medicines, Neuroplasticity, Mental Health, Ethnobotany, Therapeutic Applications.

Introduction

History and Traditional Use of Psychedelic Herbal Medicines

Indigenous societies have been using hallucinogenic plants for thousands of years; throughout this time, they were essential to religious rites, healing methods, and rituals that bonded communities. Psilocybe mushrooms and other hallucinogenic plants have been utilized by people in Mesoamerica for at least 3,000 years, according to archeological data (1). They were employed in religious rites to converse with the spiritual world by the Aztecs, who called them "divine flesh," or "teonanácatl" (2).

Similarly, Amazonian tribes have been using Ayahuasca, a hallucinogenic beverage made mostly of Psychotria viridis and Banisteriopsis caapi, to elicit visionary experiences for divination and healing for millennia (3). The Bwiti religion in Central Africa emphasizes the plant's ability to promote reflection and ancestry by including Tabernanthe iboga into spiritual rites and initiation procedures (4).

*** Corresponding Author:**

Gaurav Mude

Research Scholar, Institute of Pharmaceutical Science, SAGE University, Indore (MP), India.

Email Id: gaurav21pharmamude@gmail.com

Additionally, Salvia divinorum has long been used for divination and spiritual healing by the Mazatec people of Oaxaca, who often chew the leaves or make infusions for religious rituals (5). These customs demonstrate the intricate ethnomedical systems in which hallucinogenic substances served as instruments for psychological, emotional, and social well-being in addition to physical healing (6).

Modern Research

Driven by increasing interest in these compounds' psychopharmacological qualities, modern scientific study on psychedelics started in the early-to-mid 20th century. Early research in the 1950s and 1960s revealed encouraging therapeutic uses for psilocybin and LSD in the treatment of existential anguish, depression, and alcoholism (7).

Political and cultural changes in the late 1960s, however, caused a general ban on psychedelic research. Classified as Schedule I drugs, psychedelics greatly limited scientific research (8). Beginning in the 1990s, the resurgence of psychedelic research intensified into the 21st century. Recent research has shown that psilocybin-assisted therapy may lead to quick and lasting decreases in treatment-resistant depression and major depressive disorder (9,10).

Studies on Ayahuasca have shown its possible efficacy in treating treatment-resistant depression, drug

misuse, and post-traumatic stress disorder (PTSD) via processes including improved emotional control and neuroplasticity (11). Research on ibogaine has shown strong anti-addictive properties, particularly for opioid use disorders (12). Salvia divinorum and its active component salvinorin A are being investigated, meanwhile, for their unusual interactions with the kappa-opioid receptor, maybe providing knowledge on how to treat mood and cognitive problems (13).

Modern clinical investigations are defined by strict methods including randomized controlled trials, brain imaging studies (fMRI, PET), and multidisciplinary approaches combining psychiatry, neurology, and ethnopharmacology. These developments are opening the way for the reintegration of psychedelic treatments into conventional medicine under carefully controlled settings (14).

Table 1: Comparison of Traditional and Modern Uses of Psychedelic Plants

Psychedelic Plant	Traditional Use	Modern Research Application
***Psilocybe* mushrooms**	Spiritual rituals, healing ceremonies	Depression, anxiety, addiction therapy
Ayahuasca	Shamanic visions, communal healing	PTSD, depression, emotional regulation therapies
Tabernanthe iboga	Initiation rites, spiritual communion	Opioid addiction treatment
Salvia divinorum	Divination, religious ceremonies	Mood disorders, cognitive flexibility research

Types of Psychedelic Herbal Medicines

Ayahuasca

One of the traditional ingredients in the Amazonian drink known as ayahuasca is the plant Psychotria viridis, which contains the hallucinogenic compound N, N-Dimethyltryptamine, or DMT, and Banisteriopsis caapi, which contains monoamine oxidase inhibitors (15). Although DMT is inert when taken orally, the synergy of these plants makes it capable of producing strong psychedelic effects, such as altered states of consciousness, emotional introspection, and vivid visions (16).

Spiritual healing, communicating with spirits, and illness diagnosis are the traditional applications of Ayahuasca among Amazonian communities (17). Through enhancing emotional control and neuroplasticity, Ayahuasca has been shown in recent clinical trials to considerably alleviate PTSD, anxiety, and depression symptoms (18). Ayahuasca alters brain areas including the default mode network that are involved in self-referential processing and emotional regulation, according to neuroimaging research (19).

Psilocybin Mushrooms

Popularly known as "magic mushrooms," psilocybin mushrooms are really fungi that contain the prodrug psilocybin, which is converted into the hallucinogenic molecule psilocin (20). Many of the more than 180 kinds of Psilocybe mushrooms utilized in ancient Mayan rituals are still in use today (21).

Recent clinical trials have shown that psilocybin may help with a variety of mental health issues, including major depressive disorder, anxiety about dying, and addiction (22, 23). According to neuroscientific research, psilocybin mainly changes brain connection patterns by acting as an agonist at the serotonin 2A receptor, which in turn reduces inflexible activity in the default mode network (24). Positive effects on mental health have been associated with psilocybin's ability to induce deep sensations of connection, ego disintegration, and spiritual importance (25).

Peyote and San Pedro Cacti

Two psychotropic cacti, one native to South America (Echinopsis pachanoi) and the other to North America (Lophophora williamsii), are found in the Americas. The phenethylamine alkaloid mescaline is present in both plants and is responsible for eliciting strong emotions and dazzling hallucinations (26).

For more than five thousand years, indigenous communities in the American Southwest and northern Mexico have utilized peyote in religious rituals as a means of healing and connecting with the divine (27). The San Pedro cactus, which is widely utilized for holistic treatment and divination, also has a long history in Andean shamanic activities (28).

According to recent research, mescaline shows promise as a therapeutic tool for treating addiction and mood disorders, and it also has a decreased potential for misuse (29). Researchers have shown that mescaline may promote mystical experiences, emotional breakthroughs, and heightened openness, all of which are psychological variables linked to better treatment results (30).

Table 2: Summary of Key Psychedelic Herbal Medicines

Plant/Source	Active Compound(s)	Traditional Use	Modern Research Focus
Banisteriopsis caapi + *Psychotria viridis*	DMT, Harmine	Amazonian healing, spiritual communication	Depression, PTSD, emotional regulation
Psilocybe spp.	Psilocybin, Psilocin	Mesoamerican rituals, spiritual guidance	Depression, anxiety, addiction treatment
Lophophora williamsii (Peyote) / *Echinopsis pachanoi* (San Pedro)	Mescaline	Healing rituals, divine communion	Mood disorders, addiction therapy

Therapeutic Potential of Psychedelic Herbal Medicines

Mental Health Disorders

There is encouraging evidence that psychedelic drugs produced from herbal medicines, such psilocybin, Ayahuasca, and cacti containing mescaline, may be used to treat a range of mental health issues. One or two sessions of psilocybin have been shown to significantly alleviate symptoms of major depressive disorder and treatment-resistant depression in clinical studies (31). Psilocybin improves emotional processing and causes neuroplastic alterations by acting on serotonin 2A receptors (32).

In a similar vein, Ayahuasca has been associated with quick and long-lasting antidepressant benefits in those with anxiety and depression. Research indicates that the beverage improves emotional control by influencing brain networks such as the limbic system and the default mode network (33). Anxieties can be alleviated with the use of psychedelics, according to a meta-analysis that suggests the mystical-type experiences that are a key component of these treatments (34).

Addiction Treatment

One new way to treat addiction is via psychedelic-assisted therapy. One of the distinctive anti-addictive effects of the alkaloid ibogaine identified in Tabernanthe iboga is its effectiveness against opioid and cocaine dependency (35). The actions of ibogaine on the dopaminergic and glutamatergic circuits may explain why it alleviates cravings and withdrawal symptoms (36).

Research on psilocybin's potential as a treatment for alcohol and nicotine addiction has also been extensive. Eighty percent of smokers who took part in a seminal pilot research that used psilocybin-assisted treatment continued to abstain from smoking six months later (37). The results of this study provide evidence that psychedelic-induced states of heightened awareness, emotional liberation, and connectivity may promote substantial behavioral modification and sustained abstinence (38).

End-of-life Anxiety

Anxiety and profound existential crisis are common among terminally sick individuals. One potential solution to these serious mental health issues is psilocybin treatment. A single psilocybin session may considerably decrease anxiety and despair associated with end-of-life, according to controlled clinical investigations (39). The benefits of the session can continue up to six months.

Psychedelic users often report better spiritual health, less anxiety about dying, and a more accepting attitude toward mortality following their trips (40). Brain imaging investigations corroborate these findings by demonstrating that psilocybin inhibits activity in regions linked to fixation on one's own thoughts and feelings (41). Results from preliminary investigations into the use of ayahuasca for comparable purposes have been positive, suggesting that it may help terminally ill patients achieve emotional reconciliation and tranquility (42).

Table 3: Summary of Therapeutic Applications of Psychedelic Herbal Medicines

Condition	Substance	Proposed Mechanism	Clinical Outcomes
Major Depressive Disorder	Psilocybin	5-HT2A receptor activation, neuroplasticity	Rapid and sustained symptom reduction (39).
Opioid and Cocaine Addiction	Ibogaine	Dopamine system modulation, craving reduction	Decreased withdrawal symptoms and relapse rates (40).
Smoking and Alcohol Addiction	Psilocybin	Mystical experience, behavior change facilitation	High long-term abstinence rates (41).
End-of-life Anxiety	Psilocybin, Ayahuasca	Emotional processing, existential acceptance	Reduced depression and anxiety at 6-month follow-up (42).

Traditional Uses of Psychedelic Herbal Medicines

Many different civilizations have a long history of using psychedelic botanical medicines for ceremonial, medicinal, and spiritual reasons. Mesoamerican, South American, and African ancient cultures recognized the medicinal, hallucinogenic, and enlightening properties of these plants and used them in rituals for healing, initiation, and other life transitions.

The Aztecs held Psilocybin mushrooms (of the genus Psilocybe) in the highest regard; they called them teonanácatl, meaning "flesh of the gods," and used them as part of their sacred ceremonies to invoke healing and divine contact (43). Indigenous Amazonian communities have employed Ayahuasca, a mixture of Banisteriopsis caapi and Psychotria viridis, for shamanic purposes, including illness diagnosis, spiritual insight, and healing, for generations (44).

Native American spiritual traditions in North America revolved around the Peyote cactus (Lophophora williamsii). In order to promote spiritual connection, moral reflection, and physical healing, the peyote cactus is consumed during rites that are being practiced by the Native American Church today (45). Traditionally, the Bwiti people of Gabon used iboga, scientifically known as Tabernanthe iboga, for initiation ceremonies and psycho-spiritual healing trips. The psychedelic effects of ibogaine were thought to provide direction and a link to one's ancestors (46).

Traditional applications declined due to colonial persecution and religious prohibition from the 1600s to the 1900s, but there has been a recent upturn of interest, often combining indigenous wisdom with contemporary therapeutic frameworks (47).

Table 6: Traditional Psychedelic Herbal Medicines and Their Cultural Roles

Plant	Region/Culture	Traditional Use	Spiritual/Healing Purpose
Psilocybin Mushrooms	Aztecs, Mesoamerica	Religious rituals, healing ceremonies	Divine communication, soul purification
Ayahuasca	Amazonian tribes	Shamanic healing, spiritual journeys	Diagnosis, spiritual insight
Peyote	Native American Church	Communal prayer meetings	Spiritual communion, moral introspection
Iboga	Bwiti religion (Gabon)	Initiation rites, psycho-spiritual healing	Ancestral connection, personal healing

Safety and Risks Associated with Psychedelic Herbal Medicines

The therapeutic advantages of psychedelic plant medicines are encouraging, but there are significant hazards and safety concerns associated with their usage. Strict ceremonial frameworks were often a part of traditional usage in indigenous contexts, which served to reduce the likelihood of negative consequences. There are more valid safety concerns when utilized outside of these circumstances.

Psychological Risks

The majority of the negative side effects associated with psychedelic usage are thought to be psychological. Some of these symptoms include sudden, severe anxiety, panic attacks, paranoia, and, very rarely, psychosis in susceptible people (48).

In the absence of adequate psychological preparation or support, users may be overwhelmed by the strong emotional experiences triggered by psilocybin and ayahuasca, for instance (49).

On top of that, you might have hallucinogen persistent perception disorder (HPPD), an extremely uncommon medical disease where you keep seeing hallucinations even after the medication has stopped working (50). People who have a history of psychotic illnesses, including schizophrenia, either in themselves or their families are usually not allowed to participate in psychedelic treatment studies (51).

Physiological Risks

There are nevertheless hazards, even if physiological toxicity is often lower than that of synthetic medications. Some foods and drugs may have harmful interactions with the monoamine oxidase inhibitors (MAOIs) included in ayahuasca, which might cause hypertensive crises or serotonin syndrome (52). Mescaline, found in peyote and San Pedro cactus, has the potential to induce vomiting and nausea as well as cardiovascular side effects such as rapid heartbeat and elevated blood pressure (53).

Significant cardiotoxic hazards, such as QT interval prolongation and potentially lethal arrhythmias, are associated with the alkaloid ibogaine, which is produced from Tabernanthe iboga (54). The significance of medical screening and monitoring should be considered when contemplating the therapeutic use of ibogaine, since cases of sudden cardiac death have been linked to its usage.

Dependence and Abuse Potential

There is no evidence of physiological reliance on traditional psychedelics like psilocybin, DMT (in ayahuasca), and mescaline, in contrast to many other psychoactive drugs (55). The psychological pull of strong events, however, might cause susceptible people to develop unhealthy routines.

Current Approaches to Risk Mitigation

Modern psychedelic treatment methods include thorough preparation sessions, medical tests, in-session monitoring, and integration therapy post-experience. Such systems greatly lower the frequency of negative occurrences (56).

Table 7: Common Risks Associated with Major Psychedelic Herbal Medicines

Substance	Main Risks	Preventive Measures
Psilocybin Mushrooms	Anxiety, panic, psychosis	Psychological screening, therapeutic support
Ayahuasca	Hypertensive crisis, serotonin syndrome	Dietary restrictions, medication review
Peyote/San Pedro	Nausea, tachycardia	Medical supervision for cardiovascular health
Ibogaine	Cardiac arrhythmias, death	ECG monitoring, hospitalization

Pharmacology and Mechanism of Action

Primarily via altering the serotonin system in the brain, especially the 5-hydroxytryptamine 2A (5-HT2A) receptor, psychedelic plant drugs produce their effects. This receptor's activation starts a cascade of intracellular signaling changes thought to underlie the dramatic changes in perception, emotion, and cognition typical of the psychedelic experience (57).

Serotonergic System

Structurally comparable to serotonin are compounds include mescaline (from peyote and San Pedro cactus), DMT (from ayahuasca), and psilocybin. Psilocybin binds strongly to the 5-HT2A receptor upon consumption; it is quickly dephosphorylated to psilocin, its active form. This receptor activation leads to enhanced excitatory neurotransmission, primarily in the prefrontal cortex and default mode network (DMN), producing heightened sensory perception, emotional release, and a dissolution of ego boundaries (59).

Table 8: Key Psychedelic Compounds and Their Primary Receptors

Compound	Primary Active Metabolite	Main Target Receptor	Additional Effects
Psilocybin	Psilocin	5-HT2A	Mood regulation, cognitive flexibility
DMT (Ayahuasca)	DMT	5-HT2A	Visual imagery, emotional insights
Mescaline	Mescaline	5-HT2A, adrenergic	Emotional arousal, enhanced perception
Ibogaine	Noribogaine	NMDA, kappa-opioid, 5-HT2A	Addiction modulation, dream-like states

Other Neurotransmitter Systems

Some psychedelic substances interact with opioid systems, glutamate, dopamine, sigma-1 receptors, and the serotonergic system, all of which contribute to the hallucinogenic and therapeutic effects they produce. It is believed that ibogaine's anti-addictive effects are based on its complicated pharmacology, which it displays via regulating opioid and NMDA receptors (60).

Functional magnetic resonance imaging (fMRI) research also shows that psychedelics cause a discordance in brain networks, which loosens up previously set patterns of connection and makes room for more malleable neural pathways (61). When it comes to addressing mental health issues like depression and post-traumatic stress disorder (PTSD), this occurrence is thought to be vital.

Pharmacokinetics Overview

- **Psilocybin:** Oral bioavailability is around 50%, it starts working after 20-40 minutes, and it lasts for around 4-6 hours (62).
- **DMT:** Oral delivery necessitates MAO inhibition, similar to ayahuasca, and has a rapid onset when inhaled (seconds to minutes).
- **Mescaline:** A gradual start (1-2 hours) and a long-lasting impact (up to 12 hours).
- **Ibogaine:** Ibogaine and its metabolite noribogaine have a lengthy half-life of around 7 to 10 hours.

Psychedelic Herbal Medicines in Spiritual Practices

Psychedelic plant remedies have long been an integral part of many religions' and spiritual traditions. These herbs had other purposes beyond physical treatment, including induction into altered states of consciousness, communication with the divine, and the promotion of social cohesion and cultural identity.

Indigenous and Traditional Spiritual Use

Traditional indigenous communities typically saw psilocybin mushrooms, ayahuasca, and peyote as holy sacraments rather than just recreational drugs. Shamanic rituals in the Amazon basin revolve upon ayahuasca ceremonies, which have long been used for spiritual cleansing, divination, and making a link with the spirits of the natural world (63). Native American church rites in North America have also used peyote for millennia, with the goals of fostering spiritual direction, healing, and community unity (64).

Among the ancient Mesoamerican cultures, the Aztecs and others honored psilocybin mushrooms as "teonanácatl" or "flesh of the gods" (65). To optimize spiritual insight and safety, these traditions centered on ritualized, regulated use of psychedelics, often under the tutelage of a seasoned shaman or spiritual leader.

Contemporary Revival of Spiritual Practices

The potential spiritual benefits of psychedelics have seen a significant upturn in attention throughout the last few decades. Ayahuasca is included into Christian-based spiritual rites by legitimate religious organizations in Brazil, including the Santo Daime and the União do Vegetal (UDV), who merge indigenous traditions with contemporary theological structures (66).

Also, the spiritual aspect is becoming more recognized as an important component of healing processes in the worldwide psychedelic-assisted therapy movement, particularly in the treatment of existential crisis, loss, and despair (67).

Table 9: Major Psychedelic Herbal Medicines Used in Spiritual Practices

Plant/ Compound	Traditional Spiritual Context	Contemporary Application
Ayahuasca (DMT)	Amazonian shamanism for healing and spirit contact	Santo Daime, UDV religious ceremonies
Peyote (Mescaline)	Native American Church rituals	Ceremonial use in indigenous and non-indigenous groups
Psilocybin Mushrooms	Aztec and Mayan religious rites	Psychedelic churches, mindfulness retreats
Iboga (Ibogaine)	Bwiti religion in Central Africa	Psycho-spiritual addiction recovery ceremonies

Potential for Addiction Treatment

Psychedelic herbal drugs have recently gained attention as potential therapy options for a range of addictions, such as amphetamine usage, alcoholism, cigarette addiction, and opioid dependency. Psychedelics, in contrast to traditional pharmaceutical treatments, may get to the bottom of addiction by addressing its existential and psychological aspects; they can help with emotional release, neuroplasticity, and long-term recovery (68).

Mechanisms Supporting Addiction Treatment

Psychedelics may have anti-addictive effects via many pathways:

- **Neuroplasticity enhancement:** Psychedelics promote the reconfiguration of brain networks, which is essential for breaking addictive behaviors, by

stimulating growth factors such as BDNF (Brain-Derived Neurotrophic Factor) (69).
- **Resetting reward circuits:** By altering the serotonergic, dopaminergic, and glutamatergic systems, drugs like psilocybin and ibogaine prevent maladaptive reward learning (70).
- **Psychospiritual insights:** Substance usage and desires are significantly reduced in those who have profound spiritual or ego-dissolving experiences during psychedelic sessions (71).

Key Psychedelics in Addiction Treatment
- **Ibogaine:** Its active ingredient, Tabernanthe iboga, has been successful in treating stimulant and opiate addiction by preventing withdrawal and cravings (72).
- **Psilocybin:** There is evidence from clinical trials that it may help people quit smoking and lessen their reliance on alcohol (73).
- **Ayahuasca:** There is evidence from both clinical and traditional use that it may help with trauma and depression, two of the psychological components that contribute to drug addiction (74).

Table 10: Summary of Psychedelic Compounds and Evidence in Addiction Treatment

Compound	Addiction Target	Key Mechanisms	Clinical Evidence
Ibogaine	Opioids, stimulants	NMDA antagonism, dopamine modulation	Open-label trials, observational studies (72).
Psilocybin	Tobacco, alcohol	5-HT2A agonism, psychological restructuring	Pilot clinical trials (73).
Ayahuasca	Alcohol, polysubstance abuse	MAOI action, emotional processing	Observational studies, qualitative reports (74).

Future Scopes in Psychedelic Herbal Medicine Research

Numerous interesting study pathways have been opened by the growing scientific interest in psychedelic plant medications, although there are still considerable gaps. Integration of psychedelics into larger healthcare frameworks, development of new formulations, comprehension of long-term safety profiles, and improvement of clinical trial procedures should all be priorities for future research (75).

Clinical Trials and Regulatory Advances

Optimal dosage techniques, confirmation of effectiveness, and identification of patient categories most likely to benefit need bigger randomized controlled trials, notwithstanding promising early-phase outcomes for addiction, depression, and post-traumatic stress disorder (76). In order to guarantee similar therapy results across trials, it is necessary to codify uniform criteria for setup and optimization, therapeutic preparation, and integration techniques (77).

Novel Delivery Systems and Formulations

Improving bioavailability, decreasing adverse effects, and prolonging therapeutic effects are the goals of research into sublingual formulations, transdermal patches, and nanoencapsulation of hallucinogenic chemicals (78). Another approach being studied for cognitive improvement and mood stability is microdosing, which involves using very tiny dosages that do not produce hallucinations (79).

Personalized Psychedelic Medicine

New biomarkers, genetics, and neuroimaging techniques will pave the way for more targeted psychedelic treatments. A better understanding of how each person's neurobiology and genetic markers work could lead to more effective and safer psychedelic therapies (80).

Ethical, Legal, and Cultural Considerations

Researchers of the future will face formidable cultural, legal, and ethical obstacles. We must honor the indigenous wisdom and practices that have preserved these medicines for generations and incorporate them into modern medicine without exploiting them (81). Another important objective is the guarantee of equal access to psychedelic treatments.

Table 11: Key Challenges and Research Opportunities in Psychedelic Herbal Medicine

Research Area	Current Challenge	Future Opportunity
Clinical efficacy	Small sample sizes, lack of diversity	Large, multi-center trials
Pharmacokinetics	Short half-life of some compounds	Novel delivery technologies
Personalization	Interindividual variability in response	Biomarker-driven, customized protocols
Ethical considerations	Cultural appropriation risks	Collaborative models with indigenous groups
Regulatory frameworks	Schedule I legal barriers	FDA breakthrough therapy designations

References

1. Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurología (English Edition). 2015;30(1):42-49.
2. Guzmán G. Hallucinogenic mushrooms in Mexico: an overview. Economic Botany. 2008;62(3):404-412.
3. dos Santos RG, Bouso JC, Hallak JE. Ayahuasca: pharmacology, neuroscience and therapeutic potential. Brain Res Bull. 2017; 126:89-101.

4. Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234-242.
5. Valdés LJ. Ethnopharmacology of *Salvia divinorum* and salvinorin A. Curr Top Behav Neurosci. 2018;36:283-311.
6. Schultes RE. Ethnopharmacological conservation: a key to progress in medicine. In: Prance GT, editor. *Ethnobotany and the search for new drugs*. Chichester: Wiley; 1994. p. 23-31.
7. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994-1002.
8. Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013;14(8):577-585.
9. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.
10. Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399-408.
11. Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663.
12. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Sanchez-Ramos J, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci. 1998;844:274-292.
13. Prisinzano TE. Psychopharmacology of the hallucinogenic sage *Salvia divinorum*. Life Sci. 2005;78(5):527-531.
14. Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143-166.
15. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004;102(2):111-129.
16. Riba J, McIlhenny EH, Bouso JC, Barker SA. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study. Drug Test Anal. 2015;7(7):551-556.
17. Labate BC, Cavnar C. The therapeutic use of Ayahuasca. In: Labate BC, Cavnar C, editors. *The Therapeutic Use of Ayahuasca*. Springer; 2014. p. 1-17.
18. Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663.
19. Palhano-Fontes F, Andrade KC, Tofoli LF, Santos AC, Crippa JA, Hallak JE, et al. The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the default mode network. PLoS One. 2015;10(2):e0118143.
20. Tylš F, Páleníček T, Horáček J. Psilocybin–summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24(3):342-356.
21. Guzmán G. Hallucinogenic mushrooms: diversity, traditions, use and abuse with special reference to the genus *Psilocybe*. Int J Med Mushrooms. 2008;10(2):195-216.
22. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.
23. Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399-408.
24. Preller KH, Razi A, Zeidman P, Stämpfli P, Friston KJ, Vollenweider FX. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci U S A. 2019;116(7):2743-2748.
25. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974.
26. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355.
27. El-Seedi HR, De Smet PA, Beck O, Possnert G, Bruhn JG. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of *Lophophora williamsii*. J Ethnopharmacol. 2005;101(1-3):238-242.
28. Schultes RE, Hofmann A. *Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers*. Rochester, VT: Healing Arts Press; 2001.
29. Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One. 2013;8(8):e63972.
30. Lawn W, Johnson MW, Aldridge D. Mescaline use and its relationship with substance use and mental health outcomes: a preliminary survey. J Psychopharmacol. 2021;35(4):419-429.
31. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481-489.
32. Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611-624.

33. Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663.
34. Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res. 2020;284:112749.
35. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.
36. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn WL, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci. 1998;844(1):274-292.
37. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2A receptor agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992.
38. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299.
39. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.
40. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180.
41. Carhart-Harris RL, Bolstridge M, Day CM, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl). 2018;235(2):399-408.
42. Barbosa PC, Strassman RJ, da Silveira DX, Areco K, Hoy R, Pommy J, et al. Psychological and neuropsychological assessment of the long-term users of ayahuasca: a preliminary report. J Psychoactive Drugs. 2005;37(2):193-201.
43. Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia. 2015;30(1):42-49.
44. Labate BC, Cavnar C. The therapeutic use of ayahuasca. In: Labate BC, Cavnar C, editors. The Therapeutic Use of Ayahuasca. Heidelberg: Springer; 2014. p. 1-13.
45. Halpern JH. Hallucinogens and dissociative agents naturally growing in the Americas. In: Bucci M, editor. Hallucinogens and Entheogens: Contextualizing a New Perspective on Psychedelic Drug Use. New York: Nova Science Publishers; 2004. p. 67-90.
46. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9-24.
47. Tupper KW. The globalization of ayahuasca: Harm reduction or benefit maximization? Int J Drug Policy. 2008;19(4):297-303.
48. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-Dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74-88.
49. Barrett FS, Bradstreet MP, Leoutsakos JM, Johnson MW, Griffiths RR. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol. 2016;30(12):1279-1295.
50. Halpern JH, Lerner AG, Passie T. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2018;196:114-123.
51. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620.
52. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs. 1998;30(4):367-369.
53. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355.
54. Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.
55. Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry. 2018;30(4):317-330.
56. Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. Psychol Med. 2016;46(11):2133-2140.
57. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355.
58. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357-364.
59. Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71(3):316-344.
60. Mash DC, Kovera CA, Pablo J, Tyndale R, Ervin F, Williams IC, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394-401.
61. Preller KH, Vollenweider FX. Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. 2018;36:221-256.
62. Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in healthy volunteers. Pharmaceutica Acta Helvetiae. 1997;72(3):175-184.

63. Labate BC, Cavnar C. Ayahuasca shamanism in the Amazon and beyond. Curr Drug Abuse Rev. 2014;7(3):127-136.
64. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther. 2004;102(2):131-138.
65. Guzmán G. Ethnomycology: Mushrooms and mankind. Int J Med Mushrooms. 2008;10(4):315-328.
66. McKenna DJ. Ayahuasca and human destiny. J Psychoactive Drugs. 2004;36(3):215-219.
67. Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.
68. Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Curr Top Behav Neurosci. 2018;36:361-391.
69. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170-3182.
70. Nutt DJ, Carhart-Harris RL. The current status of psychedelics in psychiatry. JAMA Psychiatry. 2021;78(2):121-122.
71. Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157-164.
72. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9-24.
73. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol. 2015;29(3):289-299.
74. Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr Drug Abuse Rev. 2013;6(1):30-42.
75. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391-410.
76. Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology. 2017;42(11):2105-2113.
77. Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: Guidelines for safety. J Psychopharmacol. 2008;22(6):603-620.
78. Hutten NRP, Mason NL, Dolder PC, Kuypers KPC. Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol. 2019;22(7):426-434.
79. Cameron LP, Olson DE. Dark classics in chemical neuroscience: Psilocybin. ACS Chem Neurosci. 2018;9(10):2344-2357.
80. Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol. 2018;32(7):811-819.
81. George JR, Michaels TI, Sevelius J, Williams MT. The psychedelic renaissance and the limitations of white psychonautical approaches: A call for indigenous and ethnic minority inclusion. J Psychedelic Stud. 2020;4(1):4-15.

*****